Xcout IntelLineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries. It also offers ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of sensorineural hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company is developing RND1, a novel hypoimmune induced pluripotent stem cell line for the development of a cell transplant candidate for the potential treatment of an undisclosed indication, as well as engages in the research and development of ILT1, an allogeneic cell transplant for the treatment of Type 1 Diabetes; and LCT-CON, an allogeneic cell transplant, as well as therapeutic products for retinal diseases, neurological diseases, ophthalmology, metabolic, and disorders and oncology. The company has a collaboration agreement with William Demant Invest for the preclinical development of ReSonance (ANP1). It also has a strategic collaboration with Factor Bioscience Inc. for the development of genetically engineered iPSC line for the company to utilize for differentiation into certain cell transplant product candidates. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.
Subscribe to see Lineage Cell Therapeutics, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Lineage Cell Therapeutics, Inc. at a glance
Lineage Cell Therapeutics, Inc. is a biotechnology company headquartered in Carlsbad, United States. It is publicly listed (LCTX) with a market capitalisation of $264.3M. Xcout tracks 23 named people at Lineage Cell Therapeutics, Inc., including Brian Culley (Chief Executive Officer, President & Director).
Lineage Cell Therapeutics, Inc. leadership
- Brian CulleyChief Executive Officer, President & Director
- Rami SkaliterChief Executive Officer of Cell Cure Neurosciences
- Jill Ann HoweChief Financial Officer
- Jill HoweChief Financial Officer
- George A. Samuel IIIGeneral Counsel & Corporate Secretary
- Harold D. WaitzVice President of Regulatory Affairs & Quality Control
17 more named people on record for Lineage Cell Therapeutics, Inc., with roles, board committees and tenure — see the full roster →
Lineage Cell Therapeutics, Inc. competitors
A few of Lineage Cell Therapeutics, Inc.'s closest competitors — see the full list of competitors and alternatives →
BioTime, Inc. was a U.S. biotechnology company focused on developing regenerative-medicine and cell-based therapies for serious medical conditions. In 2019, it changed its name to Lineage Cell Therapeutics, which continues developing cell therapies for patients with conditions including spinal cord injury, retinal disease, and cancer.
LifeCyte Innovations is a clinical-stage biopharmaceutical company that develops novel oral therapies targeting chronic inflammation to slow the progression of age-related degenerative conditions. Its primary product offering, RestoViz, is an investigational oral combination therapy designed to treat age-related macular degeneration (AMD) by reducing inflammation, oxidative stress, and drusen buildup, with additional clinical studies evaluating applications for mild cognitive impairment, Alzheimer's disease, and traumatic brain injury.
Cell Research Corporation is a biotechnology company specializing in umbilical cord lining stem cell technology and banking. The company provides products, services, and contract research related to stem cell applications for wound healing, regenerative medicine, and cosmeceuticals.
SpinalCyte is a U.S. biotechnology company developing regenerative, cell-based therapies for spinal disorders, particularly degenerative disc disease. Its work has focused on injectable allogeneic cell therapies intended to repair or regenerate damaged intervertebral discs, serving patients with spinal degeneration.
Lin BioScience is a clinical-stage biopharmaceutical company that discovers and develops novel, first-in-class drug candidates for the treatment of cancer, eye diseases, and metabolic diseases. The company serves patients with significant unmet medical needs through targeted therapies such as oral treatments for dry age-related macular degeneration, Stargardt disease, and acute leukemia.
BioRestorative Therapies, Inc. is a life sciences company dedicated to developing regenerative medicine products and therapies. Their approach primarily utilizes adult stem cell protocols to address two key areas: disc/spine disease and metabolic disorders. Within their disc/spine program, known as brtxDisc, the company's leading cell therapy candidate is BRTX-100. This treatment involves culturing mesenchymal stem cells harvested from a patient's own bone marrow (autologous) to provide a non-surgical solution for painful lumbosacral disc conditions. BRTX-100 has successfully completed Phase 1 clinical trials. The company is also advancing its Metabolic Program, named ThermoStem, which is currently in the preclinical stage. This cell-based therapy targets obesity and other metabolic ailments by employing brown adipose-derived stem cells to generate brown adipose tissue. Beyond these core programs, BioRestorative Therapies also offers an investigational curved needle device designed for delivering cells and various therapeutic materials to the spine and discs. The company fosters strategic research and development partnerships, including agreements with Rohto Pharmaceutical Co., Ltd., Pfizer, Inc., and the University of Pennsylvania. Founded in 1997 and headquartered in Melville, New York, the company was initially known as Stem Cell Assurance, Inc., before rebranding to BioRestorative Therapies, Inc. in August 2011.
Get Lineage Cell Therapeutics, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Lineage Cell Therapeutics, Inc. in Xcout Intel
- 23 named people with titles, LinkedIn and board committees
- The full competitor set, tracking, exports and API access